Gilead Sciences, Inc. (GILD) vs Novartis AG (NVS)
- Gilead Sciences, Inc. GILD 156.19 −0.75%
- Novartis AG NVS 150.62 +0.16%
Gilead Sciences, Inc. and Novartis AG are both Drug Manufacturers General companies. Novartis AG is the larger, with a market value of $275.3B against $195.1B — 1.4× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Novartis AG trades at 22.6×. Gilead Sciences, Inc. grew revenue faster over the last twelve months: 5.52% against 2.73%. Novartis AG has the higher net margin (22.5% vs −10.6%) and the higher return on invested capital (13.1% vs −4.48%). Both pay a dividend; Novartis AG yields more (3.15% vs 2.08%). Across the 22 metrics below, Novartis AG leads on 13 and Gilead Sciences, Inc. on 9.
Valuation
Profitability
| Metric | GILD | NVS | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 79.59% | 74.74% | 72.77% |
| Operating margin | (8.20%) | 30.17% | 18.77% |
| Net margin | (10.64%) | 22.50% | 8.27% |
| Free cash flow margin | 42.50% | 26.77% | 17.18% |
| Return on equity | (20.68%) | 30.37% | 5.87% |
| Return on assets | (6.17%) | 11.27% | 2.57% |
| Return on invested capital | (4.48%) | 13.14% | 6.11% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack